Loading...
The success of standard triple therapy for Helicobacter pylori has been decreasing due to the increased prevalence of antibiotic resistance. Various alternative regimens are being investigated to address this issue.
Researchers in Japan recruited H. pylori–infected patients with dyspepsia for treatment with one such regimen: sitafloxacin (a newly developed quinolone antibiotic) 100 mg and metronidazole 250 mg, both twice daily, plus rabeprazole 10 mg four times daily, for 1 week. Of the 180 participants, 45 received the regimen as first-line treatment, 41 as second-line treatment, and 94 as third-line treatment. H. pylori eradication was determined by a breath test performed 8 weeks after therapy.
The overall eradication rate in the intent-to…